Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: J Am Coll Cardiol. 2009 Dec 1;54(23):2129–2138. doi: 10.1016/j.jacc.2009.09.009

Figure 5. Effects of rosuvastatin on the primary trial endpoint, according to baseline characteristics of the JUPITER cohort.

Figure 5

[Adopted from Ridker PM, Danielson E, Fonseca FAH, Genest J, Gottto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.]